Abbott Laboratories stock reports 4.8 percent Q2 sales growth

Published on 10/04/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock was trading at USD 97.50 on October 2, 2026, while Q2 adjusted EPS reached USD 1.31. The company raised its 2026 EPS guidance.

Aquarell Chicago-Skyline Illinois Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Aquarell-Gemälde Chicago-Skyline mit Illinois-Prärie Lake Michigan goldenes Abendlicht Abenddämmerung-Panorama, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at USD 97.50 on the NYSE on October 2, 2026 at 4:02 p.m. ET, up 0.84 percent from the prior close. The healthcare company delivered 4.8 percent comparable sales growth in Q2 2026, giving its latest results a stronger operating profile ahead of the next report.

Q2 growth supports higher guidance

According to Fortune on July 16, 2026, Abbott said adjusted earnings per share reached USD 1.31 in Q2 2026 and exceeded both the guidance midpoint and consensus. Management reaffirmed comparable sales growth guidance of 6.5 percent to 7.5 percent for full-year 2026 and raised adjusted EPS guidance to USD 5.45-5.60.

The quarterly sales figure was USD 12.59 billion, up 13.0 percent on a reported basis from the prior-year quarter, according to MarketBeat. The comparison matters because comparable growth of 4.8 percent was lower than reported growth, highlighting the contribution from acquisitions and currency effects.

Analysts see room above USD 119

MarketBeat reported on October 2, 2026 that Rothschild and Co Redburn upgraded Abbott from Neutral to Buy and lifted its price target from USD 119 to USD 127. The new target is 30.3 percent above the USD 97.50 reference price.

MarketBeat's consensus on October 1, 2026 was Moderate Buy across 27 ratings firms, including 20 Buy ratings, three Strong Buy ratings and four Holds. The average 12-month target was USD 119.50, with recent targets ranging from USD 102 to USD 130, placing the average target 22.6 percent above the reference price.

Abbott Laboratories stock has a defined catalyst

Abbott is scheduled to report third-quarter 2026 results before the market opens on October 21, 2026, according to StockTitan. That report will test the company's forecast for adjusted Q3 EPS of USD 1.38-1.46 and its expectation of stronger second-half growth.

For investors, the central tension is clear: Abbott combines raised earnings guidance with a share price 27.9 percent below its 52-week high of USD 135.24. The next earnings release will show whether the planned acceleration is reaching the income statement.

Stock trades below its yearly high

Abbott Laboratories stock was trading at USD 97.50 on the NYSE on October 2, 2026 at 4:02 p.m. ET, with a market capitalization of USD 168.7 billion and a 52-week range of USD 81.97 to USD 135.24.